XSHE
300702
Market cap1.16bUSD
Oct 09, Last price
22.18CNY
1D
-0.45%
1Q
7.25%
IPO
71.48%
Name
Zhejiang Tianyu Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Tianyu Pharmaceutical Co., Ltd. is a global enterprise specializing in the entire lifecycle, from the innovation to the commercialization, of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). The company provides essential chemical building blocks for drugs targeting a diverse range of medical conditions, including cardiovascular disorders, diabetes, anti-atherosclerosis, blood coagulation issues, and asthma. In addition to its primary focus, the firm also delivers specialty chemicals and extends its services to include contract manufacturing (CMO) for other pharmaceutical entities. This Taizhou, China-based company was established in 1993.
Key people
Yongjun Tu
Executive Chairman of the Board, General Manager · since 2025
Xiujuan Wang
Chief Financial Officer · since 2021
Chuanliang Deng
Deputy General Manager, Director · since 2023
Fujun Wang
Deputy General Manager · since 2020
Guorong Zhu
Deputy General Manager · since 2016
Yan Wang
Deputy General Manager, Secretary of the Board · since 2021
Jie Lin
Director · since 2011
Xiulin Wang
Staff Elected Director · since 2025
Hanfeng Ding
Independent Director · since 2023
Jiyuan Shi
Independent Director · since 2016
Guoyun Zhang
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||